Телзап

Quick links to important sections

Телзап

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Телзап

Телзап: Definition and Pharmacological Classification

Телзап is the trade name for a synthetic, single-component medicine containing the active substance Telmisartan. Telmisartan is classified as an Angiotensin II Receptor Blocker (ARB), a distinct pharmacological class of antihypertensive agents. This classification reflects its targeted interaction with the hormonal pathways regulating vascular tone. Telmisartan functions as a highly selective antagonist for the Angiotensin II Type 1 (AT1) receptor, which is the primary site through which Angiotensin II exerts its vasoconstrictive effects. This non-peptide compound is manufactured in a solid oral dosage form, specifically the tablet, for systemic administration.


Composition and General Therapeutic Purpose

The primary objective of using Телзап is to achieve a controlled reduction in chronic elevated blood pressure. The tablet formulation contains the single active ingredient, Telmisartan, combined with solid excipients required for stability and absorption following oral administration. Telmisartan's physiological action facilitates the relaxation and widening of the arteries by blocking the AT1 receptor, thereby inhibiting natural constricting signals. The overall effect is the systematic reduction in peripheral vascular resistance, a mechanism that eases the pressure on arterial walls. This therapeutic approach is typically employed in adults with essential hypertension for long-term blood pressure control. Beyond hypertension management, the role of Telmisartan has been established in cardiovascular risk reduction, reflecting its broader application in managing cardiovascular health indicators.

Regulatory References

  1. Pritor | European Medicines Agency (EMA)
  2. Pritor | EMA EPAR

What side effects are possible with Телзап?

Possible Side Effects and Safety Information

The safety profile of Telmisartan (Телзап) is officially defined by its documented adverse reactions, which are classified according to their frequency of occurrence in regulatory sources.

Frequency-Classified Adverse Reactions

Adverse effects are grouped into categories based on official reporting standards:

  • Common (may affect up to 1 in 10 people): The most frequently reported reaction is dizziness.
  • Uncommon (may affect up to 1 in 100 people): These effects include hypotension (low blood pressure), syncope (fainting), anemia, back pain, and certain upper respiratory tract infections.
  • Rare (may affect up to 1 in 1,000 people): Rare effects include serious reactions such as angioedema, anaphylactic reaction, and the rare occurrence of sepsis (including fatal outcomes) observed in post-marketing data.

System-Organ Class Groupings

The officially listed adverse reactions involve several body systems:

  • Vascular disorders: Hypotension, orthostatic hypotension.
  • Nervous system disorders: Dizziness, somnolence.
  • Gastrointestinal disorders: Diarrhea, abdominal discomfort.
  • Musculoskeletal and connective tissue disorders: Back pain, tendon pain.
  • Renal and urinary disorders: Renal impairment, including reports of acute renal failure.

Population-Specific Safety Considerations

Official labeling defines specific restrictions for certain populations and conditions:

  • The use of Telmisartan is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury and death.
  • It is also contraindicated in patients with severe hepatic impairment or biliary obstructive disorders.
  • Hypotension and dizziness are officially noted to be more frequently observed at the start of treatment or during dose escalation.

These official safety classifications establish the documented risk boundaries of the medicine, defining which adverse effects are recognized and which patient conditions are officially restricted.

Overdose and Emergency Response

Documented Overdose Manifestations

Overdosage with Telmisartan is defined by an exaggerated therapeutic effect on blood pressure control. The most likely documented clinical manifestation is hypotension (excessive low blood pressure), which frequently leads to secondary signs such as dizziness or fainting (syncope). The regulatory labeling also specifies that heart rate changes may occur, including the presence of tachycardia (fast heart rate) or, in some cases, bradycardia (slow heart rate) due to parasympathetic stimulation.

When Urgent Medical Help Must Be Sought

Official regulatory guidance mandates that an individual seek immediate medical attention for any suspected Telmisartan overdose. Critical symptoms define a severe, life-threatening emergency and require an immediate call to emergency services. These critical signs explicitly listed in government information include the affected individual experiencing collapse, having a seizure, exhibiting trouble breathing, or being unable to be awakened (unconsciousness).

Management and Procedural Limitations

The management approach for overdosage is exclusively symptomatic and supportive. To address symptomatic hypotension, official instructions dictate placing the patient in the supine position and utilizing an intravenous infusion of normal saline if volume restoration is clinically required. A key constraint documented in official labeling is that no specific antidote is known for Telmisartan. Additionally, the drug is not removed by hemodialysis.

Therapeutic Uses of Телзап

What Телзап Treats: Main Uses and Benefits

Телзап is generally used within two primary therapeutic domains: the long-term management of high blood pressure and the management of major vascular risk.

Телзап is commonly used for the long-term management of essential hypertension, which addresses the chronic elevation of systemic arterial pressure. This therapy is considered relevant across conditions where symptomatic support is needed, specifically for managing chronic high blood pressure and providing support for vulnerable organs in high-risk patients, such as those with Type 2 Diabetes Mellitus. This use also may assist with the benefit of supporting the reduction of risk of major acute events, in adults aged 55 and older with established vascular conditions.

“This therapy supports the patient in managing long-term functional stability by helping to ease the chronic strain on the cardiovascular system.”

This approach contributes to the therapeutic benefit of managing blood pressure and helps with easing chronic strain on the vascular system. It is applied across domains where additional symptomatic support is needed.


Quick Fact: Support for Chronic Systemic Arterial Pressure Elevation

Eligibility and Restrictions for Use

Official Population Eligibility for Телзап (Telmisartan)

Телзап is approved for use in the adult population (18 years and older). The cardiovascular risk reduction indication is specific to adults aged 55 years and older who are at high risk. The safety and efficacy of the medicine have not been established for the pediatric population (under 18 years).


Absolute Contraindications

Use of Telmisartan is strictly prohibited (contraindicated) for several population groups, as defined in regulatory labeling:

  • Patients with known hypersensitivity (e.g., angioedema) to Telmisartan or any component of the formulation.
  • Pregnancy during the second and third trimesters. Discontinuation is advised immediately upon detection of pregnancy.
  • Individuals with severe hepatic impairment or biliary obstructive disorders (e.g., cholestasis).
  • Diabetic patients who are concomitantly receiving an aliskiren-containing product.

Conditional Use and Restrictions

  • Hepatic function: Contraindicated in severe impairment, but allowed with caution and a limited dose (typically maximum 40 mg daily) in mild to moderate hepatic impairment.
  • Renal function: Patients with volume or salt depletion must have this corrected before starting therapy. Use in patients with primary aldosteronism is not recommended.
  • Lactation: Official documentation advises patients to either discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

The official interaction profile for Telmisartan is structured around specific pharmacodynamic risks and pharmacokinetic alterations documented in government regulatory sources. The most stringent restriction is the formal contraindication of co-administering Telmisartan with Aliskiren in patients diagnosed with Diabetes Mellitus or renal impairment ( GFR lt 60 mL/min/1.73 m^2). This constraint defines the regulatory stance against dual blockade of the Renin-Angiotensin System (RAS).

Pharmacodynamic interactions also mandate strict caution. Co-administration with agents that increase serum potassium, such as Potassium-Sparing Diuretics or Potassium Supplements, is associated with an elevated risk of hyperkalemia. Similarly, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may cause a reduction in the antihypertensive effect of Telmisartan and increase the risk of renal function deterioration.

The profile also documents pharmacokinetic outcomes: Telmisartan demonstrably increases the plasma concentration ( C max and AUC) of Digoxin and increases serum concentrations of Lithium. Furthermore, a population-specific note indicates that Telmisartan clearance is reduced in hepatic impairment, leading to officially acknowledged increased drug exposure.

Mechanism of Action

Telzap combines two distinct mechanistic actions to influence the body's pressure-regulating systems: disrupting neuro-hormonal signaling and interfering with renal fluid dynamics. The overall mechanism is a concurrent activation of two distinct regulatory pathways.

Inhibition of the Renin-Angiotensin-Aldosterone System (RAAS)

This mechanism is primarily driven by the telmisartan component, which functions as a highly selective antagonist of the Angiotensin II Type 1 ( AT1) receptor . By preventing Angiotensin II from binding, telmisartan disrupts the signaling cascade that regulates vasoconstriction and aldosterone release. This targeted action leads to vasodilation (widening of the arteries), contributing to a core physiological change of reduced systemic vascular resistance.


Interference with Renal Sodium and Water Reabsorption

The hydrochlorothiazide component engages a separate regulatory system by acting as an inhibitor of the sodium-chloride cotransporter ( NCC) in the kidney. Inhibiting this transporter reduces the reabsorption of salt and water. This action promotes increased natriuresis (salt excretion) and diuresis (water excretion), resulting in a core physiological change of decreased plasma and extracellular fluid volume.

Dosage and Administration Information

The administration of Телзап is consistently based on a standardized, long-term protocol that requires the medicine to be taken once daily. It is available as an oral tablet in strengths of 20 mg, 40 mg, and 80 mg. The entire tablet must be swallowed whole with liquid, and administration is permitted with or without food.


Administration Parameter Guideline Specification
Route and Form Oral Tablet
Standard Frequency Once daily
Starting Dose 40 mg
Maximum Daily Dose 80 mg
Dose Titration Based on response, over a minimum of 4 weeks

For the management of elevated blood pressure, the typical initial dose is 40 mg once per day, though therapy may begin with 20 mg. The dosage may subsequently be adjusted within the 20 mg to 80 mg range, with 80 mg representing the maximum daily dose for this use. For the reduction of cardiovascular risk, the fixed dose is 80 mg once daily.

Specific instructions apply to certain patient groups. For adults with mild to moderate hepatic impairment, the daily dose must not exceed 40 mg to ensure appropriate use. Generally, no initial dosage adjustment is necessary for older adults or individuals with mild to moderate renal impairment.

Furthermore, due to the tablet's sensitivity to moisture, a special procedural condition requires the dose to be removed from the sealed blister packaging only immediately before administration. If a dose is missed, the standard procedure is to avoid taking a double dose, recommending instead that the next dose be taken at the usual scheduled time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Телзап (Telmisartan)

Evidence Supporting the Management of High Blood Pressure

A substantial body of research was conducted to examine the use of Telmisartan in adults with essential hypertension. The research primarily involves numerous short-term to intermediate-term Randomized Controlled Trials (RCTs), a common study design used in clinical evaluation, as referenced in regulatory assessments. Researchers in these trials examined key outcomes related to systemic imbalance, specifically measuring changes in both systolic and diastolic blood pressure (SBP and DBP) as primary endpoints.

The findings describe patterns observed in the studies that involve the measured change in SBP and DBP in the observed populations. These measurements were often taken using methods like 24-hour Ambulatory Blood Pressure Monitoring (ABPM) to explore the consistency of the outcomes reflecting daily functioning or activity level throughout the full day and night.

Evidence Supporting Major Cardiovascular Risk Reduction

The evidence supporting this area is derived from a limited number of very large-scale, long-term RCTs that focused on high-risk patients. These studies did not look solely at blood pressure but instead research examined a composite of hard clinical outcomes, which included cardiovascular death, non-fatal myocardial infarction (heart attack), and non-fatal stroke. The studies report how symptoms evolved in the observed populations over follow-up periods that extended up to several years, tracking the rate at which major cardiovascular events occurred in the study groups against the designated comparator.

A key area where evidence is limited relates to the incremental contribution of Telmisartan when added to patients already receiving the highest standard of care. The results apply only to the populations studied, meaning the research does not determine whether an individual will respond similarly if they have a lower baseline risk.

Research Focused on Specific Groups and Related Conditions

Research examined its use in specific patient subgroups, particularly those with Type 2 Diabetes Mellitus. Studies focused on outcomes linked to physiological strain or stress in the kidney, using markers such as the change in the level of protein (albuminuria) found in the urine. Findings indicate that this monitoring of specific renal markers was reported over defined time intervals. However, data for certain groups remain insufficient when looking for evidence on hard renal outcomes.

Evidence Gaps and Areas of Scientific Uncertainty

While substantial research contributes to the broader evidence landscape, several areas of scientific uncertainty remain. One key limitation is that the most significant cardiovascular findings results apply only to the populations studied, leaving limited information for lower-risk groups. Additionally, the follow-up durations were limited in many studies focusing on intermediate markers, meaning there is limited information for long-term outcomes regarding the observations regarding certain organ functions.

Frequently Asked Questions (FAQ)

Common questions about Телзап (FAQ)

Q: Is Телзап used for anything besides high blood pressure?

According to official product information, Телзап is indicated for two main purposes. These are the treatment of high blood pressure (hypertension) and the reduction of overall cardiovascular risk in certain patients who are at high risk for heart-related events.

Q: What happens if a person stops taking Телзап suddenly?

Regulatory guidance states that this type of medication is intended for long-term, chronic management of blood pressure. Therefore, treatment should be continued daily as prescribed. Patients are advised not to stop taking the medication abruptly unless explicitly instructed to do so by a healthcare professional.

Q: What type of medicine (drug class) does Телзап belong to?

Official sources classify the active ingredient, Telmisartan, as an Angiotensin II Receptor Blocker, or ARB. This class of medication works directly on the body’s pressure-regulating system by blocking the action of certain hormones.

Q: How is Телзап different from an ACE inhibitor medication?

Telmisartan works by blocking the Angiotensin II receptor, which is a different action than how an ACE inhibitor works to interfere with an enzyme. This distinction in the mechanism of action is associated with a much lower incidence of a persistent dry cough.

Q: Can taking Телзап cause swelling in the hands, feet, or ankles?

Swelling in the hands, feet, or lower legs is noted as a possible adverse reaction in the official product information. Official documents also note that swelling can sometimes be a sign of kidney-related issues, which are monitored during treatment.

Q: Is feeling dizzy or lightheaded a common side effect when starting Телзап?

Dizziness and lightheadedness are reported as common adverse reactions in clinical studies. This sensation is often related to temporary low blood pressure, especially when changing position quickly, such as when you stand up.

Q: Is a persistent headache a known side effect when first taking Телзап?

Headache is listed as one of the common adverse reactions reported by patients during clinical trials for the medication.

Q: How likely is the side effect of a persistent dry cough with Телзап?

Studies indicate that Angiotensin Receptor Blockers (ARBs) like Telmisartan have a much lower likelihood of causing a persistent dry cough compared to a related class of blood pressure medicines, the ACE inhibitors.

Q: Does long-term use of Телзап affect kidney function?

The official label includes warnings about impaired renal (kidney) function. The medication has the potential to cause or worsen kidney injury, especially in susceptible patients. For this reason, monitoring of kidney function may be necessary during therapy.

Q: Is it normal to feel tired or fatigued after starting Телзап?

According to the official product information, fatigue and tiredness are listed among the common adverse reactions reported by patients in clinical studies.

Q: Are there any rare but serious side effects to watch for with Телзап?

Official warnings highlight the potential for serious adverse events. These include severe allergic reactions (angioedema), a major drop in blood pressure (severe hypotension), and sudden changes to the eye, such as secondary angle-closure glaucoma.

Q: Can I take Телзап with my morning coffee or tea?

The administration instructions permit taking the tablet with or without food. However, regulatory product labeling suggests exercising caution with stimulants or large amounts of caffeine, due to the risk of additive blood pressure effects.

Q: Is it generally safe to consume a small amount of alcohol while taking Телзап?

The official counseling information suggests that alcohol consumption be avoided or strictly limited during treatment. Alcohol can increase the risk of side effects like dizziness, lightheadedness, and low blood pressure due to an additive effect.

Q: What vitamins, minerals, or herbal supplements might interact with Телзап?

Official drug interaction information specifically advises caution regarding supplements or salt substitutes containing potassium. Using these products may increase the risk of developing hyperkalemia, which is an unsafe rise in potassium levels in the blood.

Q: Does consuming a high-salt diet reduce the effectiveness of Телзап?

The medication works by promoting the excretion of salt and water, an action which is counteracted by a high-salt diet. Official text notes that fluid and salt depletion should be corrected prior to initiating therapy, suggesting that maintaining proper salt balance is important for efficacy.

Q: Are there any specific foods that can negatively interact with Телзап?

The official label does not restrict specific foods. However, because the medicine can increase the risk of high potassium (hyperkalemia), foods that are naturally very high in potassium should be discussed with a health professional.

Q: Is it safe to take cold and flu medications with Телзап?

Official patient counseling advises against self-treating common ailments like coughs, colds, or pain with over-the-counter medications. This is because some ingredients, particularly certain decongestants, may interact by raising blood pressure.

Q: How fast does Телзап start working to effectively lower blood pressure?

A noticeable reduction in blood pressure may be seen within a few hours of taking the first dose. However, official information indicates that the maximum, steady blood pressure lowering effect is typically achieved after 4 to 8 weeks of continuous therapy.

Q: If blood pressure readings become normal, should a person continue taking Телзап?

Even if blood pressure readings return to a normal range, the medication is usually prescribed for ongoing management. The official instruction is to continue taking the dose daily unless discontinuation of therapy is specifically advised by a healthcare provider.

Q: Does Телзап have a longer duration of action compared to other similar blood pressure medications?

Official pharmacokinetic information shows that Telmisartan has a long half-life, approximately 24 hours. This long half-life supports maintaining stable blood pressure control throughout the 24-hour dosing period.

Q: Is it true that Телзап can provide protection for the heart or kidneys?

Studies and official information indicate the medication is used for the reduction of cardiovascular risk in high-risk patients. Furthermore, it has demonstrated renoprotection (kidney benefit) in patients with Type 2 diabetes.

Q: Is Телзап generally considered safe for use in older adults and seniors?

According to official geriatric use sections, studies have not identified age-specific problems that would limit the general use of Telmisartan in older adults. This means studies have not identified age-specific problems that would typically necessitate special dosage adjustments based on age alone.

Q: Can people who have diabetes use Телзап safely?

Official warnings state that the medication is strictly contraindicated for use with Aliskiren in patients who have diabetes. Additionally, the medicine may increase blood sugar levels, requiring careful monitoring of glucose.

Q: What is the official regulatory guidance regarding the use of Телзап during pregnancy?

The medication is strictly contraindicated during pregnancy. Regulatory guidance states that it should be discontinued as soon as pregnancy is detected, as it can cause injury and death to the developing fetus, particularly during the second and third trimesters.

Q: Is Телзап officially indicated for treating heart failure in some regions?

The drug is officially indicated for the reduction of cardiovascular risk. While this includes reducing the composite risk of heart failure hospitalization, the official label does not list it as a dedicated treatment for established heart failure itself.

Q: According to official sources, who should generally not use Телзап?

Official sources list several contraindications, meaning conditions under which the drug is forbidden. These include known hypersensitivity to any component, a condition called anuria (lack of urine production), and co-administration with Aliskiren in patients with diabetes.

Q: Is Телзап a common first-choice medication for high blood pressure?

Professional guidelines often recommend the Angiotensin Receptor Blocker (ARB) class of medications as one of the preferred first-line treatment options for high blood pressure. This general classification includes Telmisartan.

Q: Can Телзап be taken at night instead of the morning?

The official instruction is to take the dose once daily, allowing for flexibility in timing. Some clinical data suggests that taking the dose at bedtime may support reducing nocturnal blood pressure.

Q: Does Телзап affect blood sugar or glucose levels?

The combination medication may lead to increased blood sugar (glucose) levels and changes in other electrolytes. Due to this potential effect on metabolism, monitoring of blood sugar may be necessary, particularly for patients with pre-existing diabetes.

Q: Is Телзап officially approved for use in children or adolescents?

According to the official product information, the safety and effectiveness of the medication have not been established for use in the pediatric population (children or adolescents).

Q: Can Телзап cause problems with sleeping, such as insomnia?

Insomnia itself is not always listed as a common adverse reaction. However, other common side effects like headache, dizziness, or fatigue could potentially impact a person's quality of sleep.

Q: Does Телзап have any known effect on sexual function or libido?

A change in sexual function or libido is listed as a possible adverse reaction in the official adverse event data.

Q: Why is Телзап sometimes mentioned in connection with stroke prevention?

The official indication for the reduction of cardiovascular risk is supported by clinical data that includes the prevention of stroke. This means that reducing the risk of a stroke is part of the drug's established purpose in high-risk individuals.

Q: What kind of medical monitoring (e.g., blood tests) is usually recommended when taking Телзап?

Regulatory guidelines note that monitoring certain lab values with blood tests may be necessary, especially for susceptible patients. This monitoring typically involves checking renal (kidney) function and serum electrolytes like potassium.

Q: What does the medical term 'Angiotensin Receptor Blocker' (ARB) mean in simple language?

An Angiotensin Receptor Blocker (ARB) is a type of drug that works by blocking a specific receptor in the body. This action prevents a substance called Angiotensin II from binding, which normally causes blood vessels to constrict and blood pressure to rise.

How should Телзап be stored and disposed of?

Storage and Protection Requirements

Telzap tablets must be stored at Controlled Room Temperature, specifically maintaining a range between 20 C and 25 C (68 F and 77 F). The regulatory labeling mandates protection from moisture to preserve the product's stability, which is a key handling requirement.

To ensure this protection, the tablets must be kept in their original blister packaging and should not be removed until immediately before the time of administration. The container must remain tightly closed and protected from excess heat.

Child Safety and Disposal Rules

As with all medications, Telzap must be stored out of the reach and sight of children.

For disposal, unused or expired medication must be handled according to local requirements for pharmaceutical waste. The regulatory guidance instructs that the product should not be disposed of by flushing into surface water or the sanitary sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Телзап found in:

A-Z Index: